U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827782) titled 'Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/relapsed Central Nervous System Lymphoma' on Dec. 29, 2024.
Brief Summary: This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Refractory/recurrent Central Nervous System Lymphoma
Intervention:
BIOLOGICAL: anti-CD19 CAR-NK cells
lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Second Affiliated Hospital,...